ArticleTranslational medicine @ UniSa2012
To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator.
Article in Translational medicine @ UniSa, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities.Frontiers in pharmacology · 2023Review
- Microdose Lithium Treatment Reduced Inflammatory Factors and Neurodegeneration in Organotypic Hippocampal Culture of Old SAMP-8 Mice.Cellular and molecular neurobiology · 2021Article
- Growth and differentiation factor 15 and NF-κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection.Cancer medicine · 2021Article
- Heparanase in health and disease: The neglected housekeeper of the cell?Atherosclerosis · 2019Article
- The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium-Calmodulin Dependent Transcription Factors.International journal of molecular sciences · 2018Article
- A Novel Small Peptide Inhibitor of NFOxidative medicine and cellular longevity · 2018Article
- NF-κB Members Left Home: NF-κB-Independent Roles in Cancer.Biomedicines · 2017Review
- Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.Oxidative medicine and cellular longevity · 2017Review
- Dual role of GRK5 in cancer development and progression.Translational medicine @ UniSa · 2016Article
- Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.Oncology letters · 2015Article
- PTPIP51—A New RelA-tionship with the NFκB Signaling Pathway.Biomolecules · 2015Article
- Altered gene expression patterns during the initiation and promotion stages of neonatally diethylstilbestrol-induced hyperplasia/dysplasia/neoplasia in the hamster uterus.Reproductive toxicology (Elmsford, N.Y.) · 2014Article
- N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2014Article
- Knock-down of CD44 regulates endothelial cell differentiation via NFκB-mediated chemokine production.PloS one · 2014Article
- Modulation of Redox Signaling in Chronic Diseases and Regenerative Medicine.Oxidative medicine and cellular longevityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear factor κB (NFκB) is a transcription factor that plays an important role in carcinogenesis as well as in the regulation of inflammatory response. NFκB is constitutively expressed in tumours where it induces the expression of genes which promote cell proliferation, apoptotic events, angiogenesis, invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NFκB activation that mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NFκB activity appears a potential therapeutic strategy for cancer treatment. In this review, we focus on the role of NFκB in carcinogenesis and summarize actual inhibitors of NFκB that could be potential therapeutic target in cancer therapy.
Indexed as
Identifiers
23905066PMC3728801W1860642179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.